// App-Quantinova.ai

P-347 : A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma: EMERALD-1

Researchers

Presenter

  • B. Sangro

Principal Investigators

  • M. Kudo

  • S. Qin

  • Z. Ren

  • S. Chan

  • E. Joseph

  • Y. Arai

  • H. Mann

  • S. Morgan

  • G. Cohen

  • R. Lencioni

Medical Centers

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Kinki University Faculty of Medicine, Osaka, Japan

  • Chinese PLA Cancer Center, Jinling Hospital, Nanjing, China

  • Huashan Hospital, Fudan University, Shanghai, China

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • National Cancer Center Hospital, Tokyo, Japan

  • AstraZeneca, Gaithersberg, MD, United States,

  • University of Milan, School of Medicine, Milan, Italy

Locations

  • Spain

  • Japan

  • China

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • Durvalumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved